Home » Stocks » AXGT

Axovant Gene Therapies Ltd. (AXGT)

Nov 13, 2020 - Stock symbol was changed to SIOX
Stock Price: $2.10 USD 0.00 (0.00%)
Updated Nov 12, 2021 4:00 PM EST
Market Cap 88.11M
Revenue (ttm) n/a
Net Income (ttm) -53.17M
Shares Out 43.29M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Nov 12, 2021
Last Price $2.10
Previous Close $2.10
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 2.07 - 2.17
Day's Volume 0
52-Week Range 1.41 - 6.12

News

Hide News
GlobeNewsWire - 3 months ago

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically...

PRNewsWire - 3 months ago

NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axovant Gene Therapies Ltd. ("Axovant" or the "Company") (NASDAQ: AXGT). Such investors ...

GlobeNewsWire - 3 months ago

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Dr...

GlobeNewsWire - 4 months ago

NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host a virtu...

GlobeNewsWire - 4 months ago

NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced...

Zacks Investment Research - 4 months ago

The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.

GlobeNewsWire - 4 months ago

Company on-track to report data from ongoing Phase 1/2 clinical study in Q4 2020 Company on-track to report data from ongoing Phase 1/2 clinical study in Q4 2020

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Axovant (AXGT) stock based on the movements in the options market lately.

GlobeNewsWire - 4 months ago

NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced...

GlobeNewsWire - 4 months ago

• AXO-Lenti-PD was well-tolerated with no treatment - related serious adverse events at 6 months • 2 1- point mean improvement i n UPDRS Part III “OFF” score, a 40 % improvement from baseline ...

GlobeNewsWire - 5 months ago

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the Company will pre...

The Motley Fool - 5 months ago

These underappreciated biotechnology start-ups could turn heads one day -- but not yet.

Other stocks mentioned: BBIO
Seeking Alpha - 5 months ago

AXGT has promising gene therapy results in Parkinson's Disease.

Zacks Investment Research - 5 months ago

Axovant (AXGT) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

Seeking Alpha - 5 months ago

Week 39 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Other stocks mentioned: AAPL, AXP, JPM, KO, MCD, MRK, NKE, PFE, STRO, WMT
GlobeNewsWire - 5 months ago

NEW YORK and BASEL, Switzerland, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological ...

GlobeNewsWire - 5 months ago

      - Parkinson’s Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30th, 2020, with leading movement disorder specialists

GlobeNewsWire - 6 months ago

NEW YORK and BASEL, Switzerland, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for ...

GlobeNewsWire - 7 months ago

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD           

GlobeNewsWire - 7 months ago

NEW YORK and BASEL, Switzerland, July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological d...

Zacks Investment Research - 8 months ago

Axovant Gene Therapies (AXGT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 8 months ago

NEW YORK and BASEL, Switzerland, June 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological d...

GlobeNewsWire - 8 months ago

-  Six-month data from low-dose cohort expected in Q4 2020 -  IND amended to include Type I (infantile onset) patients and to evaluate a higher dose -  Expect to initiate high-dose cohort ...

Zacks Investment Research - 9 months ago

Axovant (AXGT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 10 months ago

Top Ranked Momentum Stocks to Buy for May 5th

Other stocks mentioned: GFI, PS, ZYXI
GlobeNewsWire - 10 months ago

Company’s balance sheet is now free of debt Company’s balance sheet is now free of debt

GlobeNewsWire - 10 months ago

NEW YORK and BASEL, Switzerland, April 15, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, toda...

Zacks Investment Research - 10 months ago

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 10 months ago

NEW YORK and BASEL, Switzerland, April 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological...

GlobeNewsWire - 1 year ago

NEW YORK and BASEL, Switzerland, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten...

GlobeNewsWire - 1 year ago

NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 1...

GlobeNewsWire - 1 year ago

NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offerin...

GlobeNewsWire - 1 year ago

NEW YORK and BASEL, Switzerland, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today provided f...

GlobeNewsWire - 1 year ago

NEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological ...

Zacks Investment Research - 1 year ago

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 1 year ago

NEW YORK and BASEL, Switzerland, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which ...

Zacks Investment Research - 1 year ago

The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.

GlobeNewsWire - 1 year ago

NEW YORK and BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced ...

Zacks Investment Research - 1 year ago

Axovant Gene Therapies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlobeNewsWire - 1 year ago

NEW YORK and BASEL, Switzerland, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced...

Zacks Investment Research - 1 year ago

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 1 year ago

In the latest trading session, Axovant (AXGT) closed at $6.61, marking a +0.46% move from the previous day.

GlobeNewsWire - 1 year ago

BASEL, Switzerland, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Parag M...

Zacks Investment Research - 1 year ago

Axovant (AXGT) closed at $7.53 in the latest trading session, marking a -1.31% move from the prior day.

Benzinga - 1 year ago

Gene therapy is an emerging therapeutic area, and Axovant Gene Therapies Ltd (NASDAQ: AXGT) is an attractive play on the sector, according to Baird.

Zacks Investment Research - 1 year ago

On Axovant's (AXGT) first-quarter fiscal 2019 earnings call, investor focus will be on its progress with the investigational pipeline candidates designed to treat debilitating neurological dis...

Zacks Investment Research - 1 year ago

Axovant (AXGT) closed the most recent trading day at $7.38, moving +0.68% from the previous trading session.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Axovant Sciences.

Zacks Investment Research - 1 year ago

Perrigo (PRGO) completes previously announced acquisition of Ranir. The company raised guidance for adjusted earnings to include accretion of 10 cents from Ranir.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Axovant (AXGT) stock based on the movements in the options market lately.

About AXGT

Axovant Gene Therapies, a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Scien... [Read more...]

Industry
Biotechnology
Founded
2014
CEO
Pavan Cheruvu
Employees
38
Stock Exchange
NASDAQ
Ticker Symbol
AXGT
Full Company Profile

Financial Performance

Financial Statements